Correction to: Nature https://doi.org/10.1038/s41586-018-0217-9, published online 13 June 2018.
In the interests of transparency, the authors wish to amend the ‘Competing interests’ statement of this Article to read: “A patent application (WO2017140828A1) has been filed by INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National De La Recherche Scientifique (CNRS), Université Paris Descartes, and Assistance Publique-Hôpitaux De Paris (AP-HP) for the use of BYL719 (alpelisib) in the treatment of PIK3CA-related overgrowth spectrum (PROS/CLOVES syndrome). G.C. is the inventor.” The original Article has been corrected online.
About this article
Cite this article
Venot, Q., Blanc, T., Rabia, S.H. et al. Author Correction: Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature 568, E6 (2019) doi:10.1038/s41586-019-1109-3